Results 251 to 260 of about 3,559,122 (359)
Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin +2 more
wiley +1 more source
Quantifying Explainability in OCT Segmentation of Macular Holes and Cysts: A SHAP-Based Coverage and Factor Contribution Analysis. [PDF]
Diagnostics (Basel)Fırat İT, Fırat M, Tuncer T.
europepmc +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective This study aims to identify both fluid and neuroimaging biomarkers for CSF1R‐RD that can inform the optimal timing of treatment administration to maximize therapeutic benefit, while also providing sensitive quantitative measurements to monitor disease progression.
Tomasz Chmiela +13 more
wiley +1 more source
AttributionScanner: A Visual Analytics System for Model Validation With Metadata-Free Slice Finding. [PDF]
IEEE Trans Vis Comput GraphXuan X, Ono JP, Gou L, Ma KL, Ren L.
europepmc +1 more source
Exploratory Analysis of ELP1 Expression in Whole Blood From Patients With Familial Dysautonomia
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background Familial dysautonomia (FD) is a hereditary neurodevelopmental disorder caused by aberrant splicing of the ELP1 gene, leading to a tissue‐specific reduction in ELP1 protein expression. Preclinical models indicate that increasing ELP1 levels can mitigate disease manifestations.
Alejandra González‐Duarte +13 more
wiley +1 more source
Explainable artificial intelligence for molecular design in pharmaceutical research. [PDF]
Chem SciLamens A, Bajorath J.
europepmc +1 more source